Quick Answer
Rein Therapeutics, Inc. reported Cash and Equivalents of $3.21 million for fiscal year 2025.
Rein Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.21M | -75.0% |
| 2024 | $12.87M | -25.8% |
| 2023 | $17.34M | +233.8% |
| 2022 | $5.19M | +44.3% |
| 2021 | $3.60M | -48.9% |
| 2020 | $7.05M | +32.7% |
| 2019 | $5.31M | -50.1% |
| 2018 | $10.63M | -10.4% |
| 2017 | $11.86M | -42.7% |
| 2016 | $20.71M | +449.8% |
| 2015 | $3.77M | -39.3% |
| 2014 | $6.21M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.05M | -77.1% | -29.3% |
| June 30, 2025 | $5.72M | -73.9% | -23.0% |
| March 31, 2025 | $7.43M | -38.3% | -42.3% |
| December 31, 2024 | $12.87M | -25.7% | -27.1% |
| September 30, 2024 | $17.65M | +46.3% | -19.5% |
| June 30, 2024 | $21.92M | +66.5% | +82.0% |
| March 31, 2024 | $12.04M | +54.7% | -30.4% |
| December 31, 2023 | $17.31M | +233.3% | +43.5% |
- Rein Therapeutics, Inc. showed a decrease of -75.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2025 period, Rein Therapeutics, Inc.’s cash and equivalents has declined by 48.2% (from $6.21 million to $3.21 million).
- The most recent figure is from Rein Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: